New lawsuit alleges more drug patent games in the HIV market
A lawsuit filed yesterday by AIDS activists and unions alleges that Gilead conspired with other drug companies to block generic competition in the HIV market, Stat News reports.
Backdrop: "Combination cocktails" are often used to treat HIV, and they consist of fixed doses of medications made by different drugmakers.
- The lawsuit alleges that Gilead made deals with Bristol-Myers Squibb and Janssen to use only each others' products in these cocktails, even after the patents expired.
Why it matters: The lawsuit alleges that this scheme kept prices for HIV drugs "sky-high," even when generic versions of the cocktail components were available.
- "This gross profiteering explains why less than half of people living with HIV in the U.S. are virally suppressed, one of the lowest rates among the world's high-income countries,” Brenda Goodrow, one of the plaintiffs, said in a statement.